Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095.

TitleSubstitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095.
Publication TypeJournal Article
Year of Publication2010
AuthorsSchouten JT, Krambrink A, Ribaudo HJ, Kmack A, Webb N, Shikuma C, Kuritzkes DR, Gulick RM
JournalClin Infect Dis
Volume50
Issue5
Pagination787-91
Date Published2010 Mar 1
ISSN1537-6591
KeywordsAcquired Immunodeficiency Syndrome, Adult, Antiviral Agents, Benzoxazines, Female, Humans, Liver, Male, Middle Aged, Nevirapine, Withholding Treatment
Abstract

In AIDS Clinical Trials Group A5095, 9% of participants who experienced an adverse event related to efavirenz substituted nevirapine. Most adverse events resolved; 15 participants ultimately discontinued nevirapine therapy. Grade 3/4 hepatotoxicity was observed in 14% of individuals who substituted nevirapine, compared with 6% who continued efavirenz therapy. Substitution of nevirapine because of efavirenz toxicity was generally safe and efficacious. Clinical trials registration. NCT00013520 .

DOI10.1086/650539
Alternate JournalClin. Infect. Dis.
PubMed ID20121419
PubMed Central IDPMC2975665
Grant ListAI 51966 / AI / NIAID NIH HHS / United States
AI 69419 / AI / NIAID NIH HHS / United States
AI068636 / AI / NIAID NIH HHS / United States
AI27659 / AI / NIAID NIH HHS / United States
AI38858 / AI / NIAID NIH HHS / United States
U01 AI038858 / AI / NIAID NIH HHS / United States
U01 AI038858-06 / AI / NIAID NIH HHS / United States
UL1-RR024996 / RR / NCRR NIH HHS / United States